CJC-1295 NO DAC + Ipamorelin Dosage Chart
The CJC-1295 NO DAC + Ipamorelin peptide blend is dosed at 100 mcg–300 mcg daily via subcutaneous injection in educational protocols. A 10 mg blend reconstituted with bacteriostatic water yields about 3.33 mg/mL. This information is for research and educational use only.
- Reconstitute: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL total concentration (1.67 mg/mL each peptide).
- Typical daily range: 100–300 mcg of each peptide once daily (gradual titration).
- Easy measuring: At 3.33 mg/mL total, 1 unit = 0.01 mL ≈ 33.3 mcg of each peptide on a U-100 insulin syringe.
- Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.
This blend combines CJC-1295 (no DAC), a modified growth hormone-releasing hormone (GHRH) analog, with Ipamorelin, a selective growth hormone secretagogue (GHS)[1][2]. CJC-1295 (no DAC) produces sustained, dose-dependent GH and IGF-1 increases[1], while Ipamorelin selectively stimulates GH release without raising ACTH or cortisol[3]. This educational protocol presents a once-daily subcutaneous approach using a practical dilution for clear insulin-syringe measurements.
Dosing & Reconstitution Guide
Educational guide for reconstitution and daily dosing
Standard / Gradual Approach (3 mL = ~3.33 mg/mL total)
| Week | Daily Dose (mcg each) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 100 mcg each | 3 units (0.03 mL) |
| Weeks 3–4 | 150 mcg each | 4.5 units (0.045 mL) |
| Weeks 5–6 | 200 mcg each | 6 units (0.06 mL) |
| Weeks 7–12 | 250–300 mcg each | 7.5–9 units (0.075–0.09 mL) |
Frequency: Inject once daily subcutaneously, typically before bed or upon waking[4]. For ≤10-unit (≤0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability.
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Plan based on an 8–16 week daily protocol with gradual titration.
- Peptide Vials (CJC-1295 NO DAC + Ipamorelin, 10 mg blend each):
- 8 weeks ≈ 3 vials
- 12 weeks ≈ 4 vials
- 16 weeks ≈ 5 vials
- Insulin Syringes (U-100, 30- or 50-unit preferred for low volumes):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
- Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
- 8 weeks (3 vials): 9 mL → 1 × 10 mL bottle
- 12 weeks (4 vials): 12 mL → 2 × 10 mL bottles
- 16 weeks (5 vials): 15 mL → 2 × 10 mL bottles
- Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100-count boxes
- 12 weeks: 168 swabs → recommend 2 × 100-count boxes
- 16 weeks: 224 swabs → recommend 3 × 100-count boxes
Protocol Overview
Concise summary of the once-daily regimen.
- Goal: Support pulsatile GH release through synergistic GHRH + GHS stimulation[4].
- Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
- Dose Range: 100–300 mcg of each peptide daily with gradual titration.
- Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL total) for accurate unit measurements.
- Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Dosing Protocol
Suggested daily titration approach.
- Start: 100 mcg each peptide daily; increase by ~50 mcg every 1–2 weeks as tolerated.
- Target: 200–300 mcg each peptide daily by Weeks 5–12.
- Frequency: Once per day (subcutaneous).
- Cycle Length: 8–12 weeks; optional extension to 16 weeks.
- Timing: Typically before bed or upon waking; rotate injection sites.
Storage Instructions
Proper storage preserves peptide quality.
- Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within ~28 days; avoid freeze–thaw.
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Practical considerations for consistency and safety.
- Use new sterile insulin syringes; dispose in a sharps container.
- Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
- Inject slowly; wait a few seconds before withdrawing the needle.
- Document daily dose and site rotation to maintain consistency.
- For doses under 10 units, use 30- or 50-unit syringes for better precision.
CJC-1295 (no DAC) is a modified GHRH analog (tetrasubstituted 29-amino acid peptide) that stimulates pulsatile GH release from the pituitary[1]. Human studies demonstrate sustained, dose-dependent increases in both GH and IGF-1 with subcutaneous administration[1]. Ipamorelin is a pentapeptide GH secretagogue with a half-life of approximately 1.5–2.5 hours[5] that elicits a rapid GH pulse peaking around 40 minutes post-dose[6]. Importantly, Ipamorelin selectively increases GH without affecting ACTH, cortisol, or prolactin levels[3]. When combined, these peptides may produce synergistic GH release by acting on complementary receptor pathways[4].
Observations from preclinical and clinical literature.
- Supports sustained GH and IGF-1 elevation through pulsatile release patterns[1][2].
- Ipamorelin demonstrates selective GH release without cortisol or ACTH elevation[3].
- Once-daily dosing of CJC-1295 (no DAC) has been shown to normalize growth in animal models[2].
- Generally well tolerated; possible transient effects may include flushing, headache, or injection-site reactions.
- Some individuals report increased appetite, water retention, or tingling sensations.
Complementary strategies for best outcomes.
- Pair with a balanced, protein-forward diet tailored to energy needs.
- Combine resistance training and aerobic activity to reinforce metabolic adaptations.
- Prioritize sleep quality, as GH is predominantly released during deep sleep.
- Manage stress to support optimal hormonal balance and recovery.
General subcutaneous guidance from clinical best-practice resources[7].
Recommended Source
We recommend Pure Lab Peptides for high-purity CJC-1295 NO DAC + Ipamorelin (10 mg Blend).
Why Pure Lab Peptides?
- High-purity, third-party-tested lots with batch COAs.
- Consistent, ISO-aligned handling and documentation.
- Reliable fulfillment to maintain cold-chain integrity.
Important Note
This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment.
References
-
PubMed— Prolonged stimulation of GH and IGF-1 secretion by CJC-1295 in healthy adults
-
PubMed— Once-daily CJC-1295 normalizes growth in GHRH knockout mouse
-
PubMed— Ipamorelin, the first selective growth hormone secretagogue
-
PMC— Beyond the androgen receptor: GH secretagogues in body composition management
-
PubMed— Pharmacokinetic-pharmacodynamic modeling of ipamorelin in human volunteers
-
PubMed— Ipamorelin GH pulse kinetics and timing studies
-
CDC— Vaccine administration: subcutaneous route (angle/site; no aspiration)
-
CDC (Subcut Injection PDF)— Technique diagram and site guidance for subcutaneous injections
-
NCBI Bookshelf— Best practices for injection (asepsis, preparation, and administration)
-
Subcutaneous Drug Injection Review (PMC)— Pharmacologic considerations of the subcutaneous route
-
Frontiers in Endocrinology— Growth hormone secretagogues: history and clinical applications
-
Endocrine Reviews— Ghrelin and growth hormone secretagogues: physiology and applications
-
Pure Lab Peptides— CJC-1295 NO DAC + Ipamorelin (10 mg Blend) product page